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Abstract Although resistin has been thought to be an impor-
tant link between obesity and diabetes, recent results do not
support this hypothesis. We speculated that resistin may be
involved in in£ammatory processes and be induced by in£amma-
tory stimuli. In this study, we tested whether lipopolysaccharide
(LPS) induced resistin expression in rats. The results show that
resistin mRNA levels in white adipose tissue and white blood
cells were increased by LPS treatment. LPS also increased
resistin mRNA levels in 3T3-L1 adipocytes and human periph-
eral blood monocytes. The results suggest that resistin is in-
volved in insulin resistance and probably in other in£ammatory
responses.
( 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Resistin, a 12.5 kDa cysteine-rich protein, is synthesized
and secreted mainly by adipocytes. Steppan et al. [1] have
shown that plasma resistin levels are signi¢cantly increased
in both genetically susceptible and high fat diet-induced obese
mice and that immunoneutralization of resistin improves hy-
perglycemia and insulin resistance in high fat diet-induced
obese mice, while administration of recombinant resistin im-
pairs glucose tolerance and insulin action in normal mice;
they also showed that, in mice and 3T3-L1 adipocytes, resistin
expression is down-regulated by rosiglitazone, a new anti-dia-
betic drug. On the basis of these results, they proposed that
resistin is an important link between obesity and diabetes.
However, the role of resistin in obesity and insulin resistance
has not been con¢rmed in several recent studies. Way et al. [2]
showed that resistin expression in white adipose tissues is sig-
ni¢cantly lower in several di¡erent obese mice models than in
their lean counterparts, Le Lay et al. [3] demonstrated that a
high fat diet reduces resistin expression in several strains of
mice with di¡erent sensitivity to diet-induced obesity, and no
association was found between resistin expression in adipo-
cytes and type 2 diabetes or insulin resistance in at least three
human studies [4^6].
Resistin has also been identi¢ed as a sensor of nutritional
state in rats and has an inhibitory e¡ect on adipocyte di¡er-
entiation [7]. The sequence of the resistin gene is identical to
that of FIZZ3, a member of an in£ammatory response protein
family described by Holcomb et al. [8]. FIZZ1, the ¢rst iden-
ti¢ed protein of this family, is overexpressed during allergic
pulmonary in£ammation [8]. While analyzing the 5P £anking
sequence of resistin, we found several potential binding se-
quences for nuclear factor UB (NF-UB), Ap-1, and STAT
(unpublished observation). These transcription factors are re-
sponsible for the inducible expression of genes involved in
immune, in£ammatory, and stress responses [9,10]. In addi-
tion, resistin mRNA has been detected in mononuclear blood
cells, which also take part in in£ammatory reactions [4,5]. On
the basis of this information, we speculated that resistin may
be involved in in£ammatory processes and might be induced
by in£ammatory stimuli. We therefore measured resistin ex-
pression in adipocytes and white blood cells during in£amma-
tion induced by lipopolysaccharide (LPS), a compound of the
cell wall of Gram-negative bacteria that has been demon-
strated to induce in£ammatory reactions. Our results show
that resistin mRNA levels were increased by both in vivo
and in vitro LPS treatment.
2. Materials and methods
2.1. Animal experiments
Male Wistar rats (9 weeks old; 200^250 g), obtained from the
Animal Center of the National Taiwan University (Taipei, Taiwan),
were housed in groups of three in stainless cages on a 12-h light cycle
(7.00^19.00 h) with free access to Purina rat chow and tap water.
After removal of food for 14 h (from 19.00 to 9.00 h), the animals
were randomly assigned to LPS or control groups. Rats in the LPS
group were injected intraperitoneally (i.p.) with 3 mg/kg of Escherichia
coli LPS (3 mg/ml in phosphate-bu¡ered saline (PBS); Sigma, St.
Louis, MO, USA), while control rats were injected with PBS (1 ml/
kg). At the indicated time points, rats were killed by being placed in a
CO2 chamber and the epididymal white adipose tissue (WAT) was
removed, immediately frozen in liquid nitrogen, and stored at 370‡C.
In a subsequent study, 16 male Wistar rats (5 weeks old) were
divided into two groups and assigned for 4 weeks to the control
diet (Purina rat chow) or the same diet supplemented with rosiglita-
zone (0.012 mg/g diet) with free access to the diets and tap water.
After this period, four rats in each group were injected i.p. with LPS
or PBS as described above and the epididymal WAT was collected 4 h
later.
All animal experimental procedures followed the ‘Guide for the
Care and Use of Laboratory Animals, National Science Council, Tai-
wan’.
2.2. 3T3-L1 adipocyte cultures
Mouse 3T3-L1 preadipocytes (ATCC, Rockville, MD, USA) were
initially maintained at 37‡C in Dulbecco’s modi¢ed Eagle’s medium
(DMEM) supplemented with 10% calf serum (Gibco BRL, Life Tech-
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nologies, Rockville, MD, USA) under an atmosphere of 5% CO2. One
day after the cells reached con£uence, di¡erentiation was induced by
replacing the normal culture medium for 2 days with DMEM supple-
mented with 0.5 mM 3-isobutyl-1-methylxanthine (Sigma), 1 WM
dexamethasone (Sigma), 50 WM insulin (Sigma), and 10% fetal bovine
serum (FBS) (Gibco BRL), followed by the same medium but without
3-isobutyl-1-methylxanthine and dexamethasone for another 2 days.
The cells were then cultured in DMEM containing 10% FBS for a
further 6 days. To study the e¡ect of LPS, the cells were changed to
serum-free DMEM for 6 h, then treated with 25, 50, or75 Wg/ml of
LPS for 12 h.
2.3. Isolation of peripheral blood cells
Four hours after injection of the rats with LPS or PBS, blood was
withdrawn from the portal vein into EDTA-containing tubes. Red
blood cells (RBC) were lysed using RBC Lysis Solution (Gentra sys-
tems, Minneapolis, MN, USA) according to the manufacturer’s in-
structions, then white blood cells (WBC) were pelleted by centrifuga-
tion, and total RNA prepared as described below.
Human peripheral blood monocytes (PBMC) were isolated from
the whole blood of healthy volunteers. Brie£y, heparinized blood
was mixed with an equal volume of PBS, layered onto Histopaque
1077 (Sigma), and centrifuged for 30 min at 400Ug. The interface
containing mononuclear cells was collected and washed twice with
RPMI 1640 medium, then the cells were resuspended at 2U106
cells/ml in RPMI 1640 medium and seeded into 6-well plates. After
6 h incubation, non-adherent cells were removed and the adherent
cells (PBMC) used for total RNA isolation after incubation with
0^10 ng/ml of LPS for 4 h.
2.4. Analyses of resistin mRNA
Total cellular RNA in adipose tissue, 3T3-L1 adipocytes, and WBC
was isolated according to the method of Chomczynski and Sacchi [11].
RNA concentrations were estimated from the absorbance at 260 nm.
For Northern blot analysis, 15 Wg of total RNA was electrophoresed
on a 1% agarose-formaldehyde gel, transferred to nylon membrane,
and hybridized with 32P-labeled cDNA probes for rat or mouse re-
sistin in animal studies and 3T3-L1 cell line studies, respectively. The
blot was then hybridized with a probe for 18S RNA to check the
amount of RNA loaded on the gel.
Levels of resistin mRNA in human PBMC were determined by RT-
PCR. Brie£y, 4 Wg of RNA was annealed with 1 Wl of oligo-dT primer
(10 WM) and reverse transcribed with 2 units of MMLV reverse tran-
scriptase at 42‡C for 60 min in a ¢nal volume of 20 Wl. For the PCR
reaction, 2 Wl of the reverse transcription mixture was used for each
reaction. Resistin mRNA was ampli¢ed for 43 cycles using the for-
ward primer 5P-TCTAGCAAGACCCTGTGCTCCA-3P and the re-
verse primer 5P-CTCAGGGCTGCACACGACAG-3P, designed ac-
cording to Steppan et al. [1]. Ampli¢cation of GAPDH mRNA for
18 cycles using the forward primer 5P-AAAGGATCCACTGGCGT-
CTTCACCACC-3P and the reverse primer 5P-GAATTCGTCATGG-
ATGACCTTGGCCAG-3P was used as the internal control. The PCR
products were separated on a 1% agarose gel, transferred to nylon
membrane, and hybridized with 32P-labeled cDNA probes for human
resistin or GAPDH.
A 509-bp rat resistin cDNA fragment, a 517-bp mouse resistin
cDNA fragment, and a 1297-bp rat 18S rRNA cDNA fragment
were ampli¢ed by RT-PCR using the following primers: rat resistin
(forward 5P-TGTGCCCTGCTGAGCTCTCT-3P ; reverse 5P-CAGAC-
CCTCATCTCGTTTCCT-3P) [7], mouse resistin (forward 5P-GGAG-
CTGTGGGACAGGAGCTA-3P ; reverse 5P-ACGTGAGTGCAGG-
TGCCTGTA-3P) [1], and rat 18S rRNA (forward 5P-TACCTGGTT-
GATCCTGCCAG-3P ; reverse 5P-TGTCAATCCTGTCCGTGTCC-
3P) [12]. The ampli¢ed DNA fragments were cloned into a pGEM-
Teasy vector (Promega, Madison, WI, USA), and sequenced to con-
¢rm their identity. The cDNA fragments were labeled with [32P]dCTP
(NEN Life Science Products, Boston, MA, USA) and used as probe
for Northern or Southern blot analyses. The signals of resistin,
GAPDH and 18S RNA were quanti¢ed by a phosphoimager (Molec-
ular Dynamics, Sunnyvale, CA, USA).
2.5. Statistical analysis
Results are expressed as the meansRS.D. Comparisons were made
using Student’s t-test. Values of P6 0.05 were considered statistically
signi¢cant.
3. Results
3.1. LPS increased resistin mRNA expression in epididymal
adipose tissue in vivo
When rats were fasted for 14 h, then injected i.p. with LPS
(3 mg/kg BW), levels of resistin mRNA in epididymal WAT
increased in a time-dependent manner (Fig. 1). A signi¢cant
(P6 0.05) 37% increase in resistin mRNA levels was detected
1 h after LPS injection, while maximal levels (113% increase;
P6 0.01) were seen 8 h after injection (Fig. 1).
3.2. Rosiglitazone treatment reduces resistin mRNA levels, but
does not prevent the LPS-induced increase in resistin
mRNA
Since resistin can be down-regulated by rosiglitazone [1], we
tested whether rosiglitazone could prevent this LPS-induced
increase in resistin mRNA. Rats were fed normal chow or
chow containing rosiglitazone for 4 weeks, then injected as
above and killed 4 h later. As in the previous experiment,
LPS treatment of control chow-fed rats resulted in a 66%
increase in resistin mRNA levels in WAT (lane 2 vs. lane 1;
P6 0.001) (Fig. 2). Although resistin mRNA levels in rosigli-
tazone-fed rats were only 40% those in the corresponding
controls (lane 3 vs. lane 1 and lane 4 vs. lane 2; P6 0.001),
LPS injection still resulted in a 66% increase in adipose resis-
tin mRNA (lane 4 vs. lane 3; P6 0.05) (Fig. 2). However,
resistin mRNA levels in LPS-injected rosiglitazone-fed rats
were only 66.5% of those seen in untreated control rats
(lane 4 vs. lane 1; P6 0.005).
Fig. 1. Resistin mRNA levels in rat epididymal WAT are increased
by in vivo LPS treatment. Fasting rats were injected i.p. with PBS
(control) or LPS (3 mg/kg BW) and total RNA was isolated from
epididymal WAT 1, 2, 4, or 8 h after injection. Resistin mRNA was
detected by Northern blotting, as described in Section 2. Upper
panels: Representative Northern blot results. Lower panels: Resistin
mRNA levels normalized to those for 18S mRNA and expressed
relative to those in the control (relative value= 100%); the results
are the meanRS.D. for three rats. *P6 0.05; **P6 0.01 compared
to the control.
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3.3. LPS increases resistin mRNA expression in 3T3-L1
adipocytes
When 3T3-L1 adipocytes were treated for 12 h with various
concentrations of LPS (0^75 Wg/ml), a dose-dependent in-
crease in resistin mRNA levels was seen (Fig. 3), with an
approximately 120% increase using 75 Wg/ml of LPS.
3.4. Resistin is expressed in rat WBC and is upregulated by
LPS in vivo
To examine the expression and response of resistin mRNA
to LPS stimulation in WBC, rats were injected with 3 mg/kg
BW of LPS (three rats) or PBS (control, two rats), then re-
sistin mRNA levels in WBC were measured 4 h later by
Northern blot analysis. Resistin mRNA was detectable in
WBC from control rats (lanes 1 and 2, Fig. 4), but the levels
were signi¢cantly lower than those in adipose tissue (data not
shown). However, a signi¢cant increase in resistin mRNA
levels (175% of control levels), mainly in the 0.8-kb mRNA,
was detected in LPS-treated rats (lanes 3^5, Fig. 4). This
result shows that, as in adipose tissue, resistin mRNA in
WBC was up-regulated by LPS.
3.5. Resistin expression in human PBMC is upregulated by
LPS in vitro
Since resistin is also expressed in mononuclear cells, we
tested the e¡ect of LPS on resistin expression in human
PBMC in vitro. When monocytes from three healthy volun-
teers were brie£y cultured, then treated for 4 h with 0, 1, 5, or
10 ng/ml of LPS, resistin mRNA levels were increased by LPS
in a dose-dependent manner (Fig. 5). A 220% increase in
resistin mRNA levels was seen in cells treated with 1 ng/ml
of LPS (lane 2), and maximal expression (a 460% increase)
was seen at 10 ng/ml LPS (lane 4). The response to LPS
induction varied slightly in monocytes from di¡erent volun-
teers, but all three samples showed an obvious increase after
LPS treatment.
4. Discussion
The present study shows that LPS increased resistin mRNA
levels in rat WAT and WBC in vivo and in mouse 3T3-L1
adipocytes and human PBMC in vitro. LPS administration, a
widely used experimental model of infection and in£amma-
tion, induces hyperglycemia and insulin resistance in rats
Fig. 2. E¡ect of rosiglitazone on WAT resistin mRNA expression in
control and LPS-injected rats. Rats were fed Purina rat chow (lanes
1 and 2) or the same diet containing rosiglitazone (0.012 mg/g diet)
(lanes 3 and 4) for 4 weeks. Four rats in each group were then in-
jected with PBS (lanes 1 and 3) or LPS (3 mg/kg BW; lanes 2 and
4) and killed 4 h after injection. Levels of resistin mRNA in epidi-
dymal WAT were detected and the results expressed as described in
Fig. 1; the values are the meanRS.D. for four rats. *P6 0.005
compared to control-fed/PBS-injected rats (lane 1); #P6 0.05 com-
pared to rosiglitazone-fed/PBS-injected rats (lane 3).
Fig. 3. LPS-induced resistin mRNA expression in 3T3-L1 adipo-
cytes. 3T3-L1 adipocytes in serum-free medium were incubated for
12 h with a ¢nal concentration of 0, 25, 50 or 75 Wg/ml of LPS,
then resistin mRNA was detected by Northern blotting as described.
Similar results were obtained in two independent experiments.
Fig. 4. Resistin mRNA levels in rat WBC are increased by in vivo
LPS treatment. Fasting rats were injected with PBS (two rats, lanes
1 and 2) or LPS (three rats, lanes 3^5) as described in Section 2,
then, 4 h later, WBC were isolated and resistin mRNA assayed by
Northern blotting as described.
Fig. 5. Resistin mRNA levels in cultured human PBMC with or
without LPS treatment. Human blood monocytes, isolated as de-
scribed in Section 2, were treated for 4 h with 0, 1, 5, or 10 ng/ml
of LPS. Resistin mRNA was detected by RT-PCR (A), then trans-
ferred to a nylon membrane and probed with a 32P-labeled cDNA
probe (B). Cells from three individuals were tested, with similar re-
sults.
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[13,14] and humans [15]. However, the mechanism of LPS-
induced insulin resistance is still poorly understood. Since
resistin has been identi¢ed as a signaling molecule that can
impair glucose tolerance and insulin action [1], our results
suggest that it may be involved in insulin resistance during
LPS-induced in£ammation. During the submission of this
manuscript, Rajala et al. [16] reported down-regulation of
resistin in adipose tissue of FVB mice upon LPS treatment.
The con£icting results could be due to di¡erent doses or peri-
ods of LPS treatment, or the use of a di¡erent animal model.
In Rajala’s study, FVB mice were injected with 100 ng/g BW
LPS and resistin response was evaluated 24 h post injection,
while in our study, Wistar rats were injected with 3 mg/kg BW
LPS for 1, 2, 4 or 8 h. As shown in Fig. 1, resistin mRNA
increased as early as 1 h after LPS injection and the highest
increase was seen at 8 h. We also observed an 86% increase of
adipose resistin mRNA when C57BL/6J mice were injected
with 3 mg/kg LPS for 4 h (unpublished data).
Systematic administration of LPS is known to increase the
release of several cytokines and other cellular mediators, such
as tumor necrosis factor-K (TNF-K), interleukin (IL)-1, and
IL-6, from the peripheral immune system via activation of
NF-UB, Ap-1, and/or STAT [9,10]. It is possible that LPS
induces resistin expression in monocytes via one of these path-
ways. However, the mechanism by which LPS induces gene
expression in adipocytes is less well understood. Kapur et al.
[17] have shown that expression of inducible nitric oxide syn-
thase in 3T3-L1 adipocytes is not induced by LPS alone, but
is induced by the combination of LPS, TNF-K, and interfer-
on-Q (IFN-Q). Grunfeld et al. [18] have shown that induction
of leptin expression in adipose tissue by LPS can be mimicked
by IL-1 and/or TNF-K. Our study showed that LPS alone,
although at a relatively high concentration (75 Wg/ml), was
able to increase resistin mRNA levels in 3T3-L1 adipocytes.
Whether IL-1, IL-6, and/or IFN-Q are also involved in resistin
regulation remains unclear. Apparently LPS-induced resistin
expression is independent of TNF-K, since TNF-K lowers re-
sistin mRNA levels in 3T3-L1 adipocytes [19]. The mechanism
whereby LPS stimulates resistin expression in adipocytes re-
mains to be established. Our in vitro studies showed that 3T3-
L1 adipocytes and isolated human PBMC respond to LPS
with increased resistin mRNA expression (Figs. 3 and 5).
These in vitro systems may provide a useful model for study-
ing the regulation of resistin gene expression.
Regardless of the mechanism by which LPS stimulates re-
sistin expression, increased resistin levels are likely to have
important physiological consequences. Two recent human
studies showed higher resistin mRNA levels in mononuclear
blood cells than in isolated adipocytes [4,5]. In this study, we
further demonstrated that resistin expression in human PBMC
was stimulated by LPS (Fig. 5), resistin mRNA levels being
increased more than two-fold by 4 h treatment with 1 ng/ml of
LPS and 5.6-fold using 10 ng/ml of LPS. This e¡ect could be
of physiological importance in man. These characteristics of
resistin are striking similar to those of TNF-K and IL-6, two
other proin£ammatory cytokines expressed in both adipocytes
and monocytes [20] ; furthermore, all three factors have im-
portant e¡ects on lipid and glucose metabolism [21] and are
involved in obesity-related insulin resistance [1,22]. In addi-
tion, resistin belongs to the FIZZ in£ammatory protein family
[8]. Taken together, these results suggest that, like TNF-K and
IL-6, resistin may participate in in£ammatory processes.
In agreement with the results of Steppan et al. [1], rosigli-
tazone decreased resistin mRNA levels by 60% in the WAT of
non-obese Wistar rats (lane 3, Fig. 2). However, it markedly
increased the mass of the epididymal WAT by 53% compared
to control rats (data not shown), this e¡ect being attributable
to the fact that it activates the peroxisome proliferator-acti-
vated receptor (PPAR)-Q and induces adipocyte di¡erentia-
tion. Several recent studies suggest that PPAR agonists may
modulate LPS-induced cytokine production [9,23,24]. How-
ever, rosiglitazone did not inhibit LPS-induced resistin expres-
sion in rats, since LPS caused a 65% increase in resistin
mRNA levels in both control and rosiglitazone-treated rats
(Fig. 2). These results suggest that LPS and rosiglitazone reg-
ulate resistin expression through di¡erent pathways.
Resistin has been reported to be expressed exclusively in
adipocytes [1], but the present study showed that it was also
expressed in rat WBC and human monocytes. We also dem-
onstrated that resistin mRNA expression was up-regulated by
LPS in these cells. In addition, we observed that resistin
mRNA was detectable in THP-1 cells (a human monocytic
leukemia cell line) and in Raw264.7 cells (a mouse macro-
phage cell line) and that its levels in these cells could be in-
creased by LPS or phorbol myristate acetate (unpublished
data). Our ¢ndings provide evidence that resistin may be in-
volved in insulin resistance and probably in other in£amma-
tory responses. The precise physiological function of resistin
during in£ammation remains unclear and deserves further in-
vestigation.
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